Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance ; volume:24 ; number:1 ; day:10 ; month:3 ; year:2024 ; pages:1-13 ; date:12.2024
Cancer cell international ; 24, Heft 1 (10.3.2024), 1-13, 12.2024
- Urheber
-
Chen, Wanxian
Geng, Deyi
Chen, Jiasheng
Han, Xiaosha
Xie, Qihu
Guo, Genghong
Chen, Xuefen
Zhang, Wancong
Tang, Shijie
Zhong, Xiaoping
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-024-03280-x
- URN
-
urn:nbn:de:101:1-2405122112120.324201716240
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Chen, Wanxian
- Geng, Deyi
- Chen, Jiasheng
- Han, Xiaosha
- Xie, Qihu
- Guo, Genghong
- Chen, Xuefen
- Zhang, Wancong
- Tang, Shijie
- Zhong, Xiaoping
- SpringerLink (Online service)
Ähnliche Objekte (12)
Aberrant splicing and drug resistance in AML
Immunotherapy of malignant melanoma
PDIVAS: Pathogenicity predictor for Deep-Intronic Variants causing Aberrant Splicing
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Dominantly inherited myosin IIa myopathy caused by aberrant splicing of MYH2
Detection of aberrant splicing events in RNA-seq data using FRASER
Roles of alternative splicing in modulating transcriptional regulation
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
The age of enlightenment in melanoma immunotherapy
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
All reported non-canonical splice site variants in GLA cause aberrant splicing
Aberrant splicing and drug resistance in AML
Immunotherapy of malignant melanoma
PDIVAS: Pathogenicity predictor for Deep-Intronic Variants causing Aberrant Splicing
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Dominantly inherited myosin IIa myopathy caused by aberrant splicing of MYH2
Detection of aberrant splicing events in RNA-seq data using FRASER
Roles of alternative splicing in modulating transcriptional regulation
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
The age of enlightenment in melanoma immunotherapy
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma
All reported non-canonical splice site variants in GLA cause aberrant splicing
Aberrant splicing and drug resistance in AML
Immunotherapy of malignant melanoma
PDIVAS: Pathogenicity predictor for Deep-Intronic Variants causing Aberrant Splicing
Aberrant DNA methylation in melanoma: biomarker and therapeutic opportunities
Dominantly inherited myosin IIa myopathy caused by aberrant splicing of MYH2
Detection of aberrant splicing events in RNA-seq data using FRASER
Roles of alternative splicing in modulating transcriptional regulation
Beyond PD-1 Immunotherapy in Malignant Melanoma
Advances in predictive biomarkers for melanoma immunotherapy
The age of enlightenment in melanoma immunotherapy
Pseudoprogression with Neoadjuvant Immunotherapy for Cutaneous Melanoma